Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

About MaverickNY

Here are my most recent posts

Posts by MaverickNY

It’s time for a BSB subscribers Q&A!

We haven’t done a mailbag for a while as things have been pretty hectic, but the end of a week is often a good time to consider this.

Here we take another look at the dismal, if very slowly evolving, SCLC landscape… there are some disturbances in the force here as well as some good and bad news to ponder.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ESMO18 is rapidly approaching with only a week to go before the conference kicks off in Munich this year.

Munich

So far in our Preview series we have highlighted what to watch out for in the late breakers, neoantigens, as well as the oral talks and poster discussions.

Now it’s time to turn our focus on the nuggets or gems that can be gleaned from the poster halls – there’s always a few pleasant surprises in store. There are small and large pharma/biotech companies included in this latest list on a wide range of therapeutics and tumour types.

There are also some interesting emerging trends, as well as hints of what might happen with some future phase 3 readouts that could catch a few people by surprise.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

The ESMO 2018 Congress is fast approaching (Twitter hashtag: #ESMO18) and BSB will be in Munich diligently providing on-site coverage for subscribers.

Old Town Hall, Munich

Over 2000 abstracts will be presented on the latest cancer immunotherapy research, biomarkers and translational research.

We’ll have plenty to write about, plus we hope to record some interviews that we may excerpt on the Novel Targets Podcast, so stay tuned for that too.

In our third preview, we highlight what we think are key abstracts to watch out for in Munich outside of the late breakers (those are covered here) in terms of how they advance our thinking and move the field forward, or could impact clinical practice.

Here we go – ESMO18 Preview 3 Top 10 Oral Abstracts to watch out for…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Times Square, New York

New York – Every now and then you go to a cancer conference and instead of hearing the expected standard talk that is repeated time and time again for a season or so, you are delighted with a more engaging and uninhibited approach that captivates and informs on the latest state of the art progress.

It also means that more than the presenter realises is perhaps shared.  That’s very good news indeed for intrepid science writers and anyone who cares to listen or read.

The research mentioned in today’s post falls in the engaged and delighted category…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

 

 

 

A warm welcome for Nobel Laureate Dr Jim Allison at CICON18

With all the furore and excitement over Dr Jim Allison’s Nobel prize award that hit CICON18 on Monday, it would be fair to say it was the highlight of the conference for many and it was pretty cool to be there in New York at the time.

Aside from the external news, there were also some intriguing developments to report on the CAR T cell therapy front – you might be forgiven for thinking that there’s not much new to say with two products now approved, but I have to point out that this is a very active area of research and there’s much going on here that is well worth highlighting.

Cell therapy is a bit like the twilight zone in the city that never sleeps – there’s a different vibe and energy about this particular research niche in oncology and quite a few new developments to discuss…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Heading Downtown for #CICON18

New York – It’s always good to see cancer researchers receive a Nobel prize.

I don’t think anyone at #CICON18 was surprised to see Dr Jim Allison as a recipient.  I’m delighted to see Prof Honjo was also recognised too, as he discovered the PD-1 checkpoint target:

Moving on it’s time for some highlights of the first day of the meeting – a couple of interesting findings emerged from the proceedings…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

The 2018 European Society for Medical Oncology (#ESMO18) Congress will take place in Munich from October 19 to 23 and it’s a meeting we’re looking forward to covering on Biotech Strategy Blog.

We’ll have “boots on the ground” in Munich.

ESMO 2018 Banner

One of the highlights of the ESMO Congress are the late-breaking abstracts, for which ESMO keeps open multiple slots in their program. As a result, the meeting provides an opportunity to hear some of the latest data.

The titles and times for most of the late-breakers have now been published in the on line program, so what can we look forward to at ESMO18?

In our first Preview we’ve highlighted several to watch out for, why we think they are noteworthy and in many cases, what the potential significance might be in a broader context.

Please note that the abstracts for late breakers aren’t typically available until the start of the congress session in which they will be presented or if they’re in the press program, until after the press briefing, so we’re not discussing any data in this post.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Toronto Skyline for WCLC

There’s a lot going on in lung cancer of late, especially with the World Conference on Lung Cancer (WCLC) taking place in Toronto this week.

Following on from our recent preview, it’s time to take a look at the actual data presented and make an assessment on progress with both targeted and immunotherapies.

Here we offer some thoughts and insights on 16 key trials that were presented…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Increasingly we are seeing more research on the inflammatory status of the tumour microenvironment (TME) in recent years, not to mention the impact of cytokine and chemokine signalling pathways, and how they can be manipulated therapeutically.

There’s also a much wider range of novel immunotherapy approaches being evaluated such as checkpoints, CARs and vaccines with respect to both T and NK cell therapies. There are also a few other immune cells being targeted for developmental therapeutics.

As part of the ongoing CICON18 Preview series, we take a look at what’s in store and why the latest ten we’ve highlighted matter in the broader context of the evolving landscape…

For those who missed it, Part 1 can be found here.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

4th CRI-CIMT-EATI-AACR meeting in NYC

The next conference we plan on attending will be the 4th CRI-CIMT-EATI-AACR meeting in New York starting on Sun 30th Sept.

Having been to the 3rd annual event in Mainz meeting last Fall, I have to say it was absolutely fantastic and well organised, with plenty of researchers giving some excellent science based talks.  There was also a heavy focus on neoantigens and neoepitopes in the poster halls, making it a good place to learn from up and coming young European researchers keen to share and discuss their work.

To find out what’s in store this time around on US soil, we took a look at the program and came up with the first of our previews exploring some interesting topics…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Sign Up for New Post Alerts
error: Content is protected !!